Clinical Trials Logo

Progeria clinical trials

View clinical trials related to Progeria.

Filter by:
  • Enrolling by invitation  
  • Page 1

NCT ID: NCT02579044 Enrolling by invitation - Progeria Clinical Trials

Phase I/II Trial of Everolimus in Combination With Lonafarnib in Progeria

Start date: December 2015
Phase: Phase 1/Phase 2
Study type: Interventional

This is a phase I/II dose-escalation trial of everolimus in combination with lonafarnib in Hutchinson-Gilford Progeria Syndrome (HGPS) and progeroid laminopathies (henceforth "progeria"). The study will be conducted at a single clinical site utilizing the Clinical and Translational Study Unit (CTSU) at Boston Children's Hospital. Lonafarnib will be administered at doses previously established in the pediatric population and in this population of progeria subjects. This study will first determine the dose-limiting toxicities (DLT) and the maximum tolerated dose (MTD) of everolimus when administered in combination with lonafarnib. It will then determine the efficacy of everolimus when administered at its MTD in combination with lonafarnib for disease in progeria.